Health Care Fund
Daily price w/o sales charge as of 07/26/2024
$19.72
$0.01
YTD Returns w/o sales charge as of 07/26/2024
10.11%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 06/28/2024
- Total Net Assets
- $8.57 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 3.53%
- Fund Net Expense Ratio
- 1.03%
- Number of Holdings
- 59
- Minimum Initial Investment
- $1,500+
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 9.16% | 7.54% | 0.53% | - | - | 9.80% |
Lipper Category Avg. Health/Biotechnology Funds | 4.76% | 7.15% | -1.50% | - | - | - |
MSCI ACWI Health Care Index (Net) | 7.40% | 10.70% | 3.75% | - | - | 10.01% |
w/ sales charge | 2.89% | 1.35% | -1.42% | - | - | 8.47% |
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 9.16% | 7.54% | 0.53% | - | - | 9.80% |
Lipper Category Avg. Health/Biotechnology Funds | 4.76% | 7.15% | -1.50% | - | - | - |
MSCI ACWI Health Care Index (Net) | 7.40% | 10.70% | 3.75% | - | - | 10.01% |
w/ sales charge | 2.89% | 1.35% | -1.42% | - | - | 8.47% |
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
![Devesh Karandikar Devesh Karandikar](/content/dam/shared-assets/biographies/karandikar-devesh/headshot/Karandikar-Devesh_headshot.jpg)
![Matthew R. DeCicco Matthew R. DeCicco](/content/dam/shared-assets/biographies/decicco-matt/headshot/Decicco-Matt_headshot.jpg)
![Heidi A. Lawrence Heidi A. Lawrence](/content/dam/shared-assets/biographies/lawrence-heidi/headshot/Lawrence-Heidi_headshot.jpg)
![Samantha E. Shevins Samantha E. Shevins](/content/dam/shared-assets/biographies/shevins-samantha/headshot/Shevins-Samantha_headshot.jpg)
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 9.16% | 7.54% | 0.53% | - | - | 9.80% |
Lipper Category Avg. Health/Biotechnology Funds | 4.76% | 7.15% | -1.50% | - | - | - |
MSCI ACWI Health Care Index (Net) | 7.40% | 10.70% | 3.75% | - | - | 10.01% |
w/ sales charge | 2.89% | 1.35% | -1.42% | - | - | 8.47% |
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 9.16% | 7.54% | 0.53% | - | - | 9.80% |
Lipper Category Avg. Health/Biotechnology Funds | 4.76% | 7.15% | -1.50% | - | - | - |
MSCI ACWI Health Care Index (Net) | 7.40% | 10.70% | 3.75% | - | - | 10.01% |
w/ sales charge | 2.89% | 1.35% | -1.42% | - | - | 8.47% |
Fund Expense Ratio :
Gross 3.53%
Net 1.03%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
NAV Historical Prices
Date | Net Asset Value |
---|
Portfolio
Portfolio
Holding | Sector | Assets |
---|
Eli Lilly & Co | Health Care | 9.6% |
Novo Nordisk A/S | Health Care | 7.7% |
Intuitive Surgical Inc | Health Care | 4.0% |
Natera Inc | Health Care | 3.1% |
Danaher Corp | Health Care | 3.1% |
Boston Scientific Corp | Health Care | 2.9% |
Stryker Corp | Health Care | 2.9% |
Thermo Fisher Scientific Inc | Health Care | 2.7% |
Krystal Biotech Inc | Health Care | 2.6% |
Blueprint Medicines Corp | Health Care | 2.4% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Holding | Sector | Assets |
---|
Eli Lilly & Co | Health Care | 9.5% |
Novo Nordisk A/S | Health Care | 7.4% |
Intuitive Surgical Inc | Health Care | 3.7% |
Danaher Corp | Health Care | 3.2% |
Natera Inc | Health Care | 3.1% |
Stryker Corp | Health Care | 3.0% |
Boston Scientific Corp | Health Care | 2.9% |
Thermo Fisher Scientific Inc | Health Care | 2.8% |
Blueprint Medicines Corp | Health Care | 2.4% |
Krystal Biotech Inc | Health Care | 2.3% |
AstraZeneca PLC | Health Care | 2.3% |
Regeneron Pharmaceuticals Inc | Health Care | 2.3% |
Daiichi Sankyo Co Ltd | Health Care | 2.1% |
Dexcom Inc | Health Care | 2.1% |
RxSight Inc | Health Care | 2.1% |
Neurocrine Biosciences Inc | Health Care | 2.1% |
Vertex Pharmaceuticals Inc | Health Care | 2.1% |
Cencora Inc | Health Care | 2.0% |
PROCEPT BioRobotics Corp | Health Care | 1.9% |
Glaukos Corp | Health Care | 1.8% |
TransMedics Group Inc | Health Care | 1.7% |
Merck & Co Inc | Health Care | 1.7% |
Alcon Inc | Health Care | 1.6% |
SpringWorks Therapeutics Inc | Health Care | 1.6% |
Arcellx Inc | Health Care | 1.5% |
Agilent Technologies Inc | Health Care | 1.4% |
Swedish Orphan Biovitrum AB | Health Care | 1.3% |
Terumo Corp | Health Care | 1.3% |
Crinetics Pharmaceuticals Inc | Health Care | 1.3% |
Cooper Cos Inc/The | Health Care | 1.2% |
Zealand Pharma A/S | Health Care | 1.2% |
Bridgebio Pharma Inc | Health Care | 1.2% |
Xenon Pharmaceuticals Inc | Health Care | 1.1% |
Encompass Health Corp | Health Care | 1.1% |
Argenx SE | Health Care | 1.0% |
Gerresheimer AG | Health Care | 1.0% |
Bio-Techne Corp | Health Care | 1.0% |
Repligen Corp | Health Care | 0.9% |
Vera Therapeutics Inc | Health Care | 0.9% |
Globus Medical Inc | Health Care | 0.9% |
Eisai Co Ltd | Health Care | 0.9% |
Longboard Pharmaceuticals Inc | Health Care | 0.8% |
Vaxcyte Inc | Health Care | 0.8% |
Nuvalent Inc | Health Care | 0.8% |
Ascendis Pharma A/S | Health Care | 0.8% |
Twist Bioscience Corp | Health Care | 0.7% |
Intra-Cellular Therapies Inc | Health Care | 0.7% |
Insmed Inc | Health Care | 0.7% |
Viking Therapeutics Inc | Health Care | 0.7% |
Siemens Healthineers AG | Health Care | 0.7% |
Quanterix Corp | Health Care | 0.6% |
Janux Therapeutics Inc | Health Care | 0.6% |
Merus NV | Health Care | 0.5% |
Madrigal Pharmaceuticals Inc | Health Care | 0.5% |
IDEXX Laboratories Inc | Health Care | 0.5% |
Immunovant Inc | Health Care | 0.5% |
Evolus Inc | Health Care | 0.5% |
Molina Healthcare Inc | Health Care | 0.4% |
Schott Pharma AG & Co KGaA | Health Care | 0.4% |
Immunome Inc | Health Care | 0.4% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Fees & Expenses
Fees & Expenses
Sales Charge Schedule as of 07/26/2024
Sales Charge | Dealer's Concession | Prices at Breakpoint | |
---|---|---|---|
Less than $50,000 | 5.75% | 5.00% | $20.92 |
$50,000 to $99,999 | 4.75% | 4.00% | $20.70 |
$100,000 to $249,999 | 3.95% | 3.25% | $20.53 |
$250,000 to $499,999 | 2.75% | 2.25% | $20.28 |
$500,000 to $999,999 | 1.95% | 1.75% | $20.11 |
$1,000,000 to $5,000,000 | 0.00% | 1.00% | $19.72 |
Class A shares purchased without a sales charge (commissionable NAV) will be subject to a CDSC of 1% if they are redeemed before the first day of the month in which the one-year anniversary of the purchase falls.
Expense Ratioas of 06/30/2024
Fund Gross Expense Ratio | 3.53% |
Fund Net Expense Ratio | 1.03% |
Adjusted Expense Ratio | - |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2025. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
0Documents selected
|
||||
---|---|---|---|---|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
Summary Prospectus
Publish Date:11/03/2015
|
||||
Statutory Prospectus
Publish Date:11/03/2015
|
||||
SAI
Publish Date:11/03/2015
|
||||
Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
Semi-Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
Fact Sheet
Publish Date:11/03/2015
|